Ngm Biopharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Ngm Biopharmaceuticals Inc (NGM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Ngm Biopharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 558,791M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-85.1% annualized vs trailing 12 months), vs accelerating (+59.2%) for its tracked peer group.
- Growth: Ngm Biopharmaceuticals Inc generated -99.1% revenue growth year over year in Q4 2023, vs -14.1% for its tracked competitors combined.
- Profitability: Its -16,769.7% net margin compares with 12.9% for the peer group.
- Peer revenue share: Ngm Biopharmaceuticals Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.04M compares with $1.18M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NGM Sales vs. its Competitors, Q4 2023
Ngm Biopharmaceuticals Inc reported revenue contraction of 99.09 % year on year in Q4 2023, below its competitors' combined revenue change of -14.11 %.
With a net margin of -16,769.70 %, Ngm Biopharmaceuticals Inc reported lower profitability than its competitors (12.91 %).
Ngm Biopharmaceuticals Inc generated 0.00 % of the combined sales of its peer group, down from 0.01 % a year earlier.
Ngm Biopharmaceuticals Inc vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Ngm Biopharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Ngm Biopharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (18) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Ngm Biopharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -99.1% for Ngm Biopharmaceuticals Inc. Ngm Biopharmaceuticals Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Ngm Biopharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Ngm Biopharmaceuticals Inc | No | No | No | Yes |
| Competitors combined (125) | ||||
| High-Confidence Competitors (22) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 12.50 % (1 of 8) | 12.50 % (1 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NGM Stock Performance relative to its Competitors
NGM Stock Performance relative to High-Confidence Competitors
NGM Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 2 | Climb Bio Inc | 282.9% | Outperformed |
| 3 | Praxis Precision Medicines Inc | 282.9% | Outperformed |
| 4 | Gossamer Bio Inc | 282.9% | Outperformed |
| 5 | Prelude Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Ngm Biopharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Ngm Biopharmaceuticals Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Ngm Biopharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Ngm Biopharmaceuticals Inc | 127.04 | 4.42 |
| Eli Lilly And Company | 1,034,082.40 | 79,665.80 |
| Beone Medicines Ltd | 550,872.13 | 6,128.24 |
| Abbvie Inc | 463,275.89 | 64,386.00 |
| Novartis Ag | 278,724.35 | 56,674.00 |
| Astrazeneca Plc | 252,216.14 | 58,739.00 |
| SUBTOTAL | 3,824,714.89 | 605,749.64 |
Sign in to see all competitors of Ngm Biopharmaceuticals Inc .
Sources: Ngm Biopharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Ngm Biopharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Ngm Biopharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AstraZeneca | Named by the company | 85% |
| Galmed Pharmaceuticals Ltd. | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
| Pliant Therapeutics, Inc. | Named by the company | 85% |
| Mirum Pharmaceuticals Inc | Named by the company | 85% |
| GENFIT S.A. | Named by the company | 85% |
| Artelo Biosciences Inc | Named by the company | 85% |
| Amgen | Named by the company | 85% |
| High Tide Therapeutics, Inc. | Named by the company | 85% |
| Novartis | Named by the company | 85% |
| AbbVie | Named by the company | 85% |
| GlaxoSmithKline | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
| Sagimet Biosciences inc | Named by the company | 85% |
| Chemomab Therapeutics Ltd | Named by the company | 85% |
| Curome Biosciences Co. | Named by the company | 85% |
| Ipsen S.A. | Named by the company | 85% |
| Novo Nordisk | Named by the company | 85% |
| Allergan | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| Eli Lilly | Named by the company | 85% |
| Hepagene Therapeutics, Inc. | Named by the company | 85% |
| Merck | Named by the company | 85% |
| Bayer | Named by the company | 85% |
| Dr. Falk Pharma | Named by the company | 85% |
| Iveric | Named by the company | 85% |
| Orbsen Therapeutics Ltd. | Named by the company | 85% |
| Takeda | Named by the company | 85% |
| Cascade Pharmaceuticals, Inc. | Named by the company | 85% |
| Escient Pharmaceuticals | Named by the company | 85% |
| Roche | Named by the company | 85% |
| Boehringer Ingelheim | Named by the company | 85% |
| Eisai | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Nextcure Inc | Named by the company | 85% |
| Cymabay Therapeutics Inc | Named by the company | 85% |
| Agenus Inc | Named by the company | 85% |
| 89bio Inc | Named by the company | 85% |
| Cypherpunk Technologies Inc | Named by the company | 85% |
| Cascade Bancorp | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Ngm Biopharmaceuticals Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Ngm Biopharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
Ngm Biopharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Ngm Biopharmaceuticals Inc | 127 | 44,170 | -1,423,750 |
| Eli Lilly And Company | 1,034,082 | 1,593,316 | 534,224 |
| Beone Medicines Ltd | 550,872 | 510,686 | 54,642 |
| Abbvie Inc | 463,276 | 1,129,579 | 110,807 |
| Novartis Ag | 278,724 | 752,973 | 185,566 |
| Astrazeneca Plc | 252,216 | 706,847 | 123,141 |
| PEERS TOTAL | 3,824,588 | 1,182,069 | 194,171 |
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
Ngm Biopharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Beone Medicines Ltd | United States 51.69 % |
| Pfizer Inc | United States 58.91 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Bristol myers Squibb Company | United States 67.79 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
Ngm Biopharmaceuticals Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 64.64 % (avg) | +35.4 pp |
| Operating Margin | -3,429.09 % | industry median | -3,299.2 pp |
| EBITDA Margin | -3,054.43 % | -7.39 % (avg) | -3,047.0 pp |
| Capital Intensity (Capex / Revenue) | 28.35 % | 4.93 % (avg) | +23.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Ngm Biopharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.5x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 0.4x | 4.5x | -4.1x |
| Return on Equity | -77.85 % | industry aggregate | -91.25 % |
| Return on Invested Capital | -41.41 % | -2.97 % (avg) | -38.44 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Ngm Biopharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue Growth | - | -15.62 % | -10.86 % | -28.95 % | -92.02 % |
| Operating Margin | -47.65 % | -118.85 % | -154.97 % | -300.45 % | -3,429.09 % |
| Return on Invested Capital | -9.25 % | -17.32 % | -16.39 % | -28.84 % | -41.41 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Ngm Biopharmaceuticals Inc's Strategic Group Map
Every company in Ngm Biopharmaceuticals Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Ngm Biopharmaceuticals Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Ngm Biopharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 28.35 % vs industry average 4.93 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Ngm Biopharmaceuticals Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Ngm Biopharmaceuticals Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Ngm Biopharmaceuticals Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Ngm Biopharmaceuticals Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Ngm Biopharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 3,299.2 points below the industry median.
- Return on equity 91.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-85.1% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (48.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Ngm Biopharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Ngm Biopharmaceuticals Inc | 2.10 | 7.18 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Ngm Biopharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Ngm Biopharmaceuticals Inc | Q4 2023 | -99.1 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +11.4 % | +38.4 % |
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Ngm Biopharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Ngm Biopharmaceuticals Inc | Q4 2023 | - | -57.4 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
Ngm Biopharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Ngm Biopharmaceuticals Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Ngm Biopharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Ngm Biopharmaceuticals Inc | - | 28.76 |
| Eli Lilly And Company | 38.84 | 12.98 |
| Beone Medicines Ltd | 831.68 | 89.89 |
| Abbvie Inc | 73.90 | 7.20 |
| Novartis Ag | 19.93 | 4.92 |
| Astrazeneca Plc | 24.67 | 4.29 |
| PEERS AVERAGE | 38.49 | 6.31 |
Sign in to see all peers for Ngm Biopharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.